Scholarlink

Abstract <p>Everolimus, an mTORC1 inhibitor, may also affect proteasome activity in a manner similar to bortezomib, necessitating further investigation. In this study, we employed ultrafast expression proteomics in combination with cell viability and proteasome activity assays to identify potential secondary targets of everolimus and to obtain a more comprehensive understanding of its mechanism of action across the proteomes of multiple cancer cell lines. The results were compared with those obtained for bortezomib and lonidamine, which were used as positive and negative controls for proteasome inhibition, respectively. Our findings reveal that everolimus inhibits 20S proteasome in lung (A549) and colon (HCT116) cancer cells, while having no detectable effect in breast cancer cells (MCF-7). An <i>in&#xa0;silico</i> model of everolimus interaction with 20S proteasome was built suggesting an allosteric mechanism of inhibition.</p> Graphical abstract

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Proteasome Inhibition as a Cancer Type-Specific Off-Target Effect of Everolimus in Cancer Cells

  • 期刊论文

  • 发表日期：

    2026年2月1日

查看全文
  • Anna S. Vorobeva,
  • Elizaveta M. Kazakova,
  • Leyla A. Garibova,
  • Daria D. Emekeeva,
  • Tomiris T. Kusainova,
  • Ivan I. Fedorov,
  • Andrey A. Shelepchikov,
  • Alexey V. Tretyakov,
  • Anton O. Chugunov,
  • Mikhail V. Gorshkov,
  • Irina A. Tarasova

摘要

Abstract

Everolimus, an mTORC1 inhibitor, may also affect proteasome activity in a manner similar to bortezomib, necessitating further investigation. In this study, we employed ultrafast expression proteomics in combination with cell viability and proteasome activity assays to identify potential secondary targets of everolimus and to obtain a more comprehensive understanding of its mechanism of action across the proteomes of multiple cancer cell lines. The results were compared with those obtained for bortezomib and lonidamine, which were used as positive and negative controls for proteasome inhibition, respectively. Our findings reveal that everolimus inhibits 20S proteasome in lung (A549) and colon (HCT116) cancer cells, while having no detectable effect in breast cancer cells (MCF-7). An in silico model of everolimus interaction with 20S proteasome was built suggesting an allosteric mechanism of inhibition.

Graphical abstract